Detailed Narrative
Non-GPL Business Offsets Glenmark Rationalization
Alivus Life reported a 2.2% YoY revenue growth to ₹602 crores, a figure that masks a significant shift in business mix. The external (non-GPL) business grew by 14.5% YoY and 18% in volume terms, effectively counteracting a 22% decline in business from former parent Glenmark. Management attributed the GPL decline to inventory rationalization and expressed confidence that this segment would recover in the second half of the year, maintaining a high single-digit growth target for the full year.
Margin Resilience Despite Pricing Pressures
The company achieved a stellar gross margin of 55.1%, up 400 bps YoY, and an EBITDA margin of 30.1%. This expansion was driven by rationalized input costs, better energy efficiency, and the successful launch of new products with higher margins. Despite acknowledging pricing pressures in the broader API market that will likely limit revenue growth to high single digits, management reiterated that EBITDA margins will remain sustainable in the 28% to 30% band.
CDMO Ramp-up Expected in H2 FY26
The CDMO segment remained subdued during Q1, but management anticipates a broader ramp-up in H2 FY26. Validation batches for the fifth major CDMO project have commenced, with commercialization expected in the second half. Long-term, Alivus aims to double the CDMO contribution to 12-15% of total revenue over the next 4-5 years, up from the current 6-7% level, citing high confidence due to an increasing project pipeline.
Strategic Capacity Expansion at Solapur
The Solapur facility is on track to begin operations in Q4 FY26. Initially, a significant portion of this capacity will be used for backward integration to improve the bottom line, with ROW (Rest of World) business expected to start in the first half of next year. The company has a total capex approval of ₹600 crores for FY26, which includes brownfield projects at Dahej and Ankleshwar to support the growing CDMO and specialty API demand.
Regulatory De-risking with Successful FDA Inspections
A major highlight of the quarter was the successful US FDA inspection of the Dahej facility, which received an EIR with NAI (No Action Indicated) classification. This follows a similar successful inspection at the Ankleshwar facility earlier in the year. These outcomes are significant as both large facilities had not been audited for nearly six years, effectively removing a major regulatory overhang for the company.